Table 3.
Whole cohort | P valuea | Never required iMV | Required iMV | P valueb | ||||
---|---|---|---|---|---|---|---|---|
No microbiological diagnosis (n = 101) |
Microbiological diagnosis (n = 99) |
No microbiological diagnosis (n = 47) |
Microbiological diagnosis (n = 31) |
No microbiological diagnosis (n = 54) |
Microbiological diagnosis (n = 68) |
|||
Antibiotic treatment | ||||||||
ATS guideline adherence | 71 (70%) | 21 (79%) | 0.168 | 32 (68%) | 26 (84%) | 39 (72%) | 52 (77%) | 0.43 |
Adequate empiric treatment | 70/99 (71%) | 22/31 (71%) | 48/58 (71%) | 0.97 | ||||
Change on empiric treatment | 49 (49%) | 67 (68%) | 0.006 | 18 (38%) | 16 (52%) | 31 (57%) | 51 (75%) | 0.001 |
De-escalation | 8 (8%) | 30 (30%) | < 0.001 | 3 (6%) | 5 (16%) | 5 (9%) | 25 (36%) | < 0.001 |
Continued empiric | 60 (59%) | 39 (40%) | 31 (66%) | 19 (61%) | 29 (54%) | 20 (29%) | ||
Continued empiric + add new antibiotic | 23 (23%) | 16 (16%) | 11 (23%) | 5 (16%) | 12 (22%) | 11 (16%) | ||
Escalation | 10 (10%) | 14 (14%) | 2 (4%) | 2 (6%) | 8 (15%) | 12 (18%) | ||
Empiric treatment duration, median [p25-p75] | 9 [6–10] | 7 [4–11] | 0.197 | 9 [7–11] | 8 [6–12] | 7 [5–10] | 7 [4–11] | 0.066 |
Total treatment duration, median [p25-p75] | 10 [7–15] | 14 [10–22] | 0.004 | 10 [8–14] | 13 [9–22] | 11 [7–16] | 14 [10–22] | 0.036 |
ATS American Thoracic Society, iMV invasive mechanical ventilation
aComparison between those with and without microbiological diagnosis
bOverall comparison between four groups